Briacell Therapeutics Corp T.BCT

Alternate Symbol(s): BCTX | BCTXW

Healthcare Biotechnology

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

TSX:BCT - Post by User

Briacell Therapeutics Corp

Bullboard Posts

Comment by Sh99999on May 14, 2019 8:54am

64 Views

Post# 29744092

RE:RE:RE:RE:RE:RE:Speculation

more share yesterday (1231000)

Filed 2019-05-13 16:12 Tx date 2019-05-13	$BCT BriaCell Therapeutics Corp.	Bondarenko, Jamieson 3 - 10% Security Holder of Issuer, 4 - Director of Issuer	Common Shares 10 - Acquisition or disposition in the public market	+1,231,000 vol	27,976,500